What is the recommended management strategy for autoimmune hepatitis?

Management of Autoimmune Hepatitis

First-line therapy for autoimmune hepatitis should consist of predniso(lo)ne at 0.5 mg/kg/day (up to 40 mg maximum) combined with azathioprine starting at 50 mg/day (or 1 mg/kg/day), with azathioprine initiated either simultaneously or 2 weeks after corticosteroids. 1, 2

Initial Treatment Strategy

The standard induction regimen follows this algorithmic approach:

Week 0-2:

• Start predniso(lo)ne at 0.5 mg/kg/day (maximum 40 mg) as a single morning dose
• In severe cases, increase to 1 mg/kg/day 1
• Either start azathioprine 50 mg/day immediately OR delay by 2 weeks 1
• Check TPMT enzyme activity before starting azathioprine if readily available 2

Week 2-4:

• If using mycophenolate mofetil instead (1,000 mg initially), increase to 1,500-2,000 mg/day at week 2 1
• If using azathioprine, increase to full dose of 1-2 mg/kg/day by week 4 1

Monitoring schedule:

• Check ALT and IgG at weeks 4,12, and 24 1
• Monitor CBC, liver enzymes, and safety parameters within the first month, particularly in the first 6 weeks with azathioprine when toxicity is most common 1
• After achieving complete biochemical response (CBR), follow-up every 3-6 months 1

Corticosteroid Tapering

Taper predniso(lo)ne gradually over 1-3 months to 5-10 mg/day, guided by falling transaminases 2. The tapering should be individualized based on:

• Biochemical response (ALT and IgG levels)
• Presence of complications
• Fibrosis stage 1

As steroids decrease, azathioprine can be increased from 1 to 2 mg/kg/day with appropriate blood count monitoring 2.

Alternative First-Line Option

Budesonide 9 mg/day can be considered instead of prednisolone in non-cirrhotic adults with major concerns about steroid cosmetic side effects 2. However, budesonide is contraindicated in cirrhosis due to first-pass hepatic metabolism and should not be used as first-line in children 2.

Special Populations

Decompensated cirrhosis: Use steroid monotherapy (predniso(lo)ne 0.5 mg/kg/day, maximum 40 mg) without azathioprine initially 2. These patients require careful risk-benefit assessment as they may have "burn-out" cirrhosis with low probability of benefit from immunosuppression 3.

TPMT deficiency:

• Homozygous TPMT deficiency: substitute mycophenolate mofetil for azathioprine 2
• Heterozygous (modestly reduced activity): insufficient evidence for routine dose reduction 2

Supportive Management

Bone health protection is mandatory:

• Adequate calcium intake and vitamin D supplementation for all patients on long-term corticosteroids 1, 2
• Calculate FRAX score in adults starting steroids 2
• Consider early bisphosphonates in high-risk patients pending DEXA scan 2

Pregnancy precautions with mycophenolate mofetil: All patients (male and female) must use two methods of birth control, with negative pregnancy testing at screening 1.

Monitoring Strategy

Regular non-invasive evaluation with transient elastography is recommended to monitor liver fibrosis 1. Laboratory monitoring should include:

• Every 2-3 months initially to determine CBR at 6 and 12 months 1
• Thyroid function every 6-12 months (thyroid disorders can develop during follow-up) 1
• Azathioprine metabolite levels are not routinely needed but can be considered for leucopenia or suspected non-adherence 2

Common Pitfalls to Avoid

1. Do not delay treatment initiation in patients with significant liver inflammation—the goal is to achieve remission and prevent progression to cirrhosis
2. Do not use budesonide in cirrhotic patients—it requires hepatic metabolism and is ineffective in advanced disease 2
3. Do not start azathioprine at full dose immediately—gradual escalation reduces early toxicity risk 1
4. Do not forget bone protection—up to 70% of patients report side effects and low quality of life during corticosteroid therapy 1
5. Screen for HBV before starting immunosuppression—provide prophylactic nucleotide therapy if HBV surface antigen or core antibody positive 2

Second-Line Options

For patients with inadequate response, intolerance, or loss of response to standard therapy (occurring in up to 20% of patients 4), second-line agents include mycophenolate mofetil, mercaptopurine, calcineurin inhibitors (tacrolimus, cyclosporine), and biologics such as rituximab 4, 5, 6.